AR055195A1 - Piperazin-piridinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3 y composicion farmaceutica - Google Patents
Piperazin-piridinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3 y composicion farmaceuticaInfo
- Publication number
- AR055195A1 AR055195A1 ARP060100547A ARP060100547A AR055195A1 AR 055195 A1 AR055195 A1 AR 055195A1 AR P060100547 A ARP060100547 A AR P060100547A AR P060100547 A ARP060100547 A AR P060100547A AR 055195 A1 AR055195 A1 AR 055195A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- alkylaryl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Estos compuestos son utiles para tratar enfermedades mediadas por quimiocinas, tales como terapia paliativa, terapia curativa, terapia profiláctica de ciertas enfermedades y afecciones tales como enfermedades inflamatorias (ejemplo(s) no limitativo(s) incluye(n), psoriasis), enfermedades autoinmunes (ejemplo(s) no limitativo(s) incluye(n), artritis reumatoidea, esclerosis multiple). Reivindicacion 1: Un compuesto que posee la estructura general que se muestra en la formula (1), o sales aceptables para uso farmacéutico, solvatos o ésteres del mismo donde Z es N, C(R29), NO o NOH; X es N, O, alquilo, cicloalquilo, heteroarilo, heterociclilo o heterociclenilo; R1 y R2 se encuentran independientemente ausentes o presentes y si se encuentran presentes, cada uno se selecciona independientemente del grupo que consiste en H, alquilo, alcoxi, alquenilo, carbonilo, cicloalquilo, cicloalquenilo, alquilarilo, arilalquilo, arilo, amino, alquilamino, amidinilo, carboxamido, ciano, hidroxilo, urea, -N?CH, =NCN, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNH2, -(CH2)qNHR31, -(CH2)qN(R31)2, -(CH2) qC(=O)NHR31, -(CH2)qSO2R31, -(CH2)qNHSO2R31, -(CH2)qSO2NHR31, -C(=S)N(H)alquilo, -N(H)-S(O)2-alquilo, -N(H)C(=O)N(H)-alquilo, -S(O) 2-alquilo, - S(O)2N(H)alquilo, -S(O)2N(alquilo)2, -S(O)2arilo, -C(=S)N(H)cicloalquilo, -C(=O)N(H)NH2, -C(=O)alquilo, -heteroarilo, heterociclilo, y heterociclenilo; o de manera alternativa cuando X es N, el N tomado junto con el R1 y R2 forma un heterociclo, heteroarilo o -N=C(NH2)2; los restos R3, R4, R6 y R29 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquilarilo, aralquilo, -CN, CF3, haloalquilo, cicloalquilo, halogeno, hidroxialquilo, -N=CH-(R31), -C(=O)N(R30)2, -N(R30)2, -OR30, -SO2(R31), - N(R30)C(=O)N(R30)2 y -N(R30)C(=O)R31; R7 y R8 son iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquilarilo, heteroarilo, hidroxilo, -CN, alcoxi, alquilamino, -N(H)S(O)2alquilo y -N(H)C(=O)N(H)alquilo; o de manera alternativa R7 y R8 tomados juntos son =O, =S, =NH, =N(alquilo), =N(O-alquilo), =N(OH) o cicloalquilo; los restos R10 pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, cicloalquilo, arilo, heteroarilo, heterociclenilo, heterociclilo, alquilarilo, arilalquilo, -CO2H, hidroxialquilo, -C(=O)N(R30)2, -(CH2)qOH, -(CH2)qOR31 - (CH2)qNHR31, -(CH2)qN(R31)2, -OR30, halogeno, =O, y -C(=O)R31 ; los restos R11 pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, cicloalquilo, arilo, heteroarilo, heterociclilo, heterociclenilo, alquilarilo, arilalquilo, hidroxialquilo, carboxamida, CO2H, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNHR31, -(CH2)qN(R31)2, -OR30, halogeno, =O, y -C(=O)R31; los restos R12 pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, -CN, -C(=O)N(R30)2, -(CH2)qOH, -(CH2)qOR31, -(CH2) qNHR31, -(CH2)qN(R31)2, y -S(O2)R31; D es un anillo cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterociclenilo o heterociclilo de cinco a nueve miembros que posee 0-4 heteroátomos seleccionados independientemente de O, S o N, donde el anillo D es no substituido o se encuentra opcionalmente substituido por 1-5 restos R20 seleccionados independientemente; los restos R20 pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquenilo, alquilarilo, alquinilo, alcoxi, alquilamino, alquiltiocarboxi, alquilheteroarilo, alquiltio, alquilsulfinilo, alquilsulfonilo, alcoxicarbonilo, aminoalquilo, amidinilo, aralquilo, aralquenilo, aralcoxi, aralcoxicarbonilo, aralquiltio, arilo, aroilo, ariloxi, ciano, cicloalquilo, cicloalquenilo, formilo, guanidinilo, halogeno, haloalquilo, heteroalquilo, heteroarilo, heterociclilo, heterociclenilo, hidroxialquilo, hidroxamato, nitro, trifluorometoxi, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNH2, -(CH2) qNHR31, -(CH2)qN(R31)2, -(CH2)qC(=O)NHR31, -(CH2)qSO2R31, (CH2)qNHSO2R31, -(CH2)qSO2NHR31, -alquiniloC(R31)2OR31, - C(=O)R30, - C(=O)N(R30)2, -C(=NR30)NHR30, -C(=NOH)N(R30)2, -C(=NOR31)N(R30)2, -C(=O)OR30, -N(R30)2, -N(R30)C(=O)R31, -NHC(=O)N(R30)2, - N(R30)C(=O)OR31, -N(R30)C(=NCN)N(R30)2, -N(R30)C(=O)N(R30)SO2(R31), -N(R30)C(=O)N(R30)2, -N(R30)SO2(R31), - N(R30)S(O)2N(R30) 2, -OR30, -OC(-O)N(R30)2, -SR30, -SO2N(R30)2, -SO2(R31), -OSO2(R31), y -OSi(R30)3; o de manera alternativa dos restos R20 se unen para formar un anillo arilo, cicloalquilo, heterociclilo, heterociclenilo, o heteroarilo de cinco o seis miembros donde dicho anillo arilo, cicloalquilo, heterociclilo, heterociclenilo, o heteroarilo de cinco o seis miembros se fusiona al anillo D y el anillo fusionado se substituye opcionalmente por 0-4 restos R21; los restos R21 pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquenilo, alquilarilo, alquinilo, alcoxi, alquilamino, alquiltiocarboxi, alquilheteroarilo, alquiltio, alquilsulfinilo, alquilsulfonilo, alcoxicarbonilo, aminoalquilo, amidinilo, aralquilo, aralquenilo, aralcoxi, aralcoxicarbonilo, aralquiltio, arilo, aroilo, ariloxi, carboxamido, ciano, cicloalquilo, cicloalquenilo, formilo, guanidinilo, halogeno, haloalquilo, heteroalquilo, heteroarilo, heterociclilo, heterociclenilo, hidroxialquilo, hidroxamato, nitro, trifluorometoxi, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNH2, -(CH2)qNHR31, -(CH2)qN(R31)2, -(CH2)qC(=O)NHR31, -(CH2) qSO2R31, (CH2)qNSO2R31, -(CH2)qSO2NHR31, - alquiniloC(R31)2OR31, -C(=O)R30, -C(=O)N(R30)2, -C(=NR30)NHR30, -C(=NOH)N(R30)2, - C(=NOR31)N(R30)2, -C(=O)OR30, -N(R30)2, -N(R30)C(=O)R31, -NHC(=O)N(R30)2, -N(R30)C(=O)OR31, -N(R30)C(=NCN)N(R30)2, -N(R30)C(= O)N(R30)SO2(R31), -N(R30)C(=O)N(R30)2, - N(R30)SO2(R31), -N(R30)S(O)2N(R30)2, -OR30, -OC(-O)N(R30)2, -SR30, -SO2N(R30)2, - SO2(R31), -OSO2(R31), y -OSi(R30)3;Y se selecciona del grupo que consiste en -(CR13R13)r-, -CHR13C(=O)-, -(CHR13)rO-, -(CHR13)rN(R30)-, -C(=O)-, -C(=R30)-, -C(=N-OR30)- , -CH(C(=O)NHR30)-, CH-heteroaril-, -C(R13R13)rC(R13)=C(R13)-, -(CHR13)rC(=O)- y -(CHR13)rN(H)C(= O)-; o de manera alternativa Y es cicloalquilo, heterociclenilo, or heterociclilo donde el cicloalquilo, heterociclenilo, o heterociclilo se fusiona con el anillo D; los restos R13 pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquilarilo, cicloalquilo, alcoxi, arilo, heteroarilo, heterociclenilo, heterociclilo, espiroalquilo, -CN, - CO2H, -C(=O)R30, -C(=O)N(R30)2, -(CHR30) qOH, -(CHR30)qOR31, -(CHR30)qNH2, -(CHR30)qNHR31, -(CH2)qC(=O)NHR31, -(CH2)qSO2R31, -(CH2)qNSO2R31, -(CH2)qSO2NHR31, -NH2, - N(R30)2, -N(R30)C(=O)N(R30)2, -N(R30)SO2(R31), -OH, -OR30, -SO2N(R30)2, and - SO2(R31); los restos R30 pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquilarilo, arilo, aralquilo, cicloalquilo, CN, -(CH2)qOH, -(CH2)qO-alquilo, -(CH2)qO-alquilarilo, -(CH2)qO- arilo, -(CH2)qO-aralquilo, -(CH2)qO-cicloalquilo, -(CH2)qNH2, -(CH2)qNH-alquilo, -(CH2) qN(alquilo)2, -(CH2)qNH-alquilarilo, -(CH2)qNH-arilo, -(CH2)qNH-aralquilo, -(CH2)qNH-cicloalquilo, -(CH2)qC(=O)NH-alquilo, -(CH2)qC(=O) N(alquilo)2, -(CH2)qC(=O)NH- alquilarilo, -(CH2)qC(=O)NH-arilo, -(CH2)qC(=O)NH-aralquilo, -(CH2)qC(=O)NH-cicloalquilo, -(CH2)qSO2-alquilo, -(CH2)qSO2-alquilarilo, -(CH2)qSO2-arilo, -(CH2)qSO2-aralquilo, -(CH2)qSO2-cicloalquilo, -(CH2)qNSO2-alquilo, -(CH2)qNSO2-alquilarilo, - (CH2)qNSO2-arilo, -(CH2)qNSO2-aralquilo, -(CH2)qNSO2-cicloalquilo, -(CH2)qSO2NH-alquilo, -(CH2)qSO2NH-alquilarilo, -(CH2)qSO2NH-arilo, -(CH2)qSO2NH-aralquilo, -(CH2)qSO2NH-cicloalquilo, heterociclenilo, heterociclilo, y heteroarilo; los restos R31 pueden ser iguales o diferentes seleccionándose cada uno independientemente del grupo que consiste en alquilo, alquilarilo, arilo, aralquilo, cicloalquilo, -(CH2)qOH, -(CH2)qO- alquilo, -(CH2)qO-alquilarilo, -(CH2)qO-arilo, -(CH2)qO-aralquilo, - (CH2)qO-cicloalquilo, -(CH2)qNH2, -(CH2)qNH-alquilo, -(CH2)qN(alquilo)2, -(CH2)qNH-alquilarilo, -(CH2)qNH-arilo, -(CH2)qNH-aralquilo, -(CH2)qNH-cicloalquilo, -(CH2)qC(=O)NH-alquilo, -(CH2)qC(=O)N(alquilo)2, -(CH2) qC(=O)NH-alquilarilo, -(CH2)qC(=O)NH- arilo, -(CH2)qC(=O)NH-aralquilo, -(CH2)qC(=O)NH-cicloalquilo, -(CH2)qSO2-alquilo, -(CH2)qSO2- alquilarilo, -(CH2)qSO2-arilo, -(CH2)qSO2-aralquilo, -(CH2)qSO2-cicloalquilo, -(CH2)qNSO2-alquilo, -(CH2)qNSO2-alquilarilo, -(CH2)qNSO2-arilo, -(CH2)qNSO2- aralquilo, -(CH2)qNSO2-cicloalquilo, -(CH2)qSO2NH-alquilo, -(CH2)qSO2NH-alquilarilo, -(CH2)qSO2NH-arilo, -(CH2)qSO2NH- aralquilo, -(CH2)qSO2NH-cicloalquilo, heterociclenilo, heterociclilo, and heteroarilo; m es de 0 a 4; n es de 0 a 4; cada q puede ser igual o diferente, seleccionándose cada uno independientemente de 1 a 5; y r es de 1 a 4; con la salvedad de que no exista ningun doble enlace adyacente en ningun anillo y que cuando un nitrogeno se substituye por dos grupos alquilo, dichos dos grupos alquilo se puedan unir opcionalmente entre sí para formar un anillo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65333705P | 2005-02-16 | 2005-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055195A1 true AR055195A1 (es) | 2007-08-08 |
Family
ID=36593711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100547A AR055195A1 (es) | 2005-02-16 | 2006-02-15 | Piperazin-piridinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3 y composicion farmaceutica |
Country Status (13)
Country | Link |
---|---|
US (1) | US7776862B2 (es) |
EP (1) | EP1856097B1 (es) |
JP (1) | JP2008530218A (es) |
KR (1) | KR20070107056A (es) |
CN (1) | CN101213185A (es) |
AR (1) | AR055195A1 (es) |
AU (1) | AU2006214378A1 (es) |
CA (1) | CA2598457A1 (es) |
IL (1) | IL185074A0 (es) |
MX (1) | MX2007009946A (es) |
TW (1) | TW200640901A (es) |
WO (1) | WO2006088919A2 (es) |
ZA (1) | ZA200706793B (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2297461T3 (es) | 2003-09-09 | 2008-05-01 | Fumapharm Ag | Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma. |
JP4948395B2 (ja) | 2004-04-13 | 2012-06-06 | インサイト・コーポレイション | ケモカインレセプターアンタゴニストとしてのピペラジニルピペリジン誘導体 |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
CA2598418A1 (en) * | 2005-02-16 | 2006-08-31 | Schering Corporation | Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
CA2598456A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Heterocyclic substituted piperazines with cxcr3 antagonist activity |
EP1856098B1 (en) * | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CA2598489A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
CN101146793A (zh) * | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
TW200714610A (en) * | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
US7781437B2 (en) * | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
AR059962A1 (es) * | 2006-03-21 | 2008-05-14 | Schering Corp | Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3 |
CA2658417A1 (en) * | 2006-07-14 | 2008-01-17 | Schering Corporation | Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
AR064609A1 (es) * | 2006-12-22 | 2009-04-15 | Schering Corp | Piperazinas sustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor de quimiocinas cxcr3. |
US20110112196A1 (en) | 2007-02-08 | 2011-05-12 | Matvey E Lukashev | Nrf2 screening assays and related methods and compositions |
US8835426B2 (en) * | 2007-02-26 | 2014-09-16 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
CN101678082B (zh) | 2007-03-26 | 2013-06-19 | 再生医药有限公司 | 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法 |
EP2183228B1 (en) * | 2007-07-26 | 2014-08-20 | Vitae Pharmaceuticals, Inc. | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 |
AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
CA2707492A1 (en) * | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
EP2225226B1 (en) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Compounds and their use in a method for treatment of cancer |
TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
JP5490020B2 (ja) * | 2008-01-24 | 2014-05-14 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状カルバゼート及びセミカルバジドインヒビター |
WO2009102428A2 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 |
WO2009102460A2 (en) * | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
PE20091576A1 (es) * | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
US20110105504A1 (en) * | 2008-03-18 | 2011-05-05 | Vitae Pharmaceuticals ,Inc. | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 |
JP5301563B2 (ja) | 2008-05-01 | 2013-09-25 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
CA2723039A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2291373B1 (en) * | 2008-05-01 | 2013-09-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US20110118262A1 (en) * | 2008-07-08 | 2011-05-19 | Boehringer Ingelheim International Gmbh | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors |
CA2730890C (en) | 2008-07-17 | 2018-05-15 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
TW201016691A (en) | 2008-07-25 | 2010-05-01 | Boehringer Ingelheim Int | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
NZ590495A (en) | 2008-07-25 | 2012-10-26 | Vitae Pharmaceuticals Inc | Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2010050461A1 (ja) * | 2008-10-27 | 2010-05-06 | 田辺三菱製薬株式会社 | 新規アミド誘導体およびその医薬としての用途 |
WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
CA2744946A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
KR20120061771A (ko) * | 2009-04-30 | 2012-06-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
WO2011068171A1 (ja) * | 2009-12-03 | 2011-06-09 | 第一三共株式会社 | 二環性含窒素飽和へテロ環誘導体 |
EP3235818A3 (en) | 2010-04-01 | 2018-03-14 | Critical Outcome Technologies, Inc. | Compounds for the treatment of hiv |
US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン |
WO2012000904A1 (en) | 2010-06-28 | 2012-01-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical composition for use in the treatment of glaucoma |
GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
CN104093715B (zh) | 2012-02-02 | 2017-04-26 | 埃科特莱茵药品有限公司 | 4‑(苯并咪唑‑2‑基)‑噻唑化合物及相关氮杂衍生物 |
AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
WO2015011099A1 (en) | 2013-07-22 | 2015-01-29 | Actelion Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
EP3756666A1 (en) * | 2013-12-24 | 2020-12-30 | Oncotartis Inc. | Nicotinamide compound for use in the treatment of cancer |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
US20170045378A1 (en) * | 2014-06-30 | 2017-02-16 | Toyo Tire & Rubber Co., Ltd. | Sensor for detecting deformation of sealed secondary battery, sealed secondary battery, and method for detecting deformation of sealed secondary battery |
TR201900680T4 (tr) | 2015-01-15 | 2019-02-21 | Idorsia Pharmaceuticals Ltd | CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri. |
AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
EA037555B1 (ru) | 2015-04-02 | 2021-04-13 | Проксимэйджен, Элэлси | Применение 6-{4-[1-(пропан-2-ил)пиперидин-4-ил]-1,4-диазепан-1-ил}-n-(пиридин-4-ил)пиридин-2-карбоксамида для лечения раковых заболеваний цнс |
TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07501063A (ja) | 1991-11-14 | 1995-02-02 | グラクソ、グループ、リミテッド | フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体 |
JPH07503459A (ja) | 1992-01-21 | 1995-04-13 | グラクソ、グループ、リミテッド | 酢酸誘導体 |
US6124319A (en) * | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
AR013693A1 (es) | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria |
PL203116B1 (pl) * | 1999-05-04 | 2009-08-31 | Schering Corp | Piperazynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
US20020018776A1 (en) | 2000-04-14 | 2002-02-14 | Millennium Pharmaceuticals, Inc. | Method of treating graft rejection using inhibitors of CXCR3 function |
EP1343505A1 (en) * | 2000-12-11 | 2003-09-17 | Tularik Inc. | Cxcr3 antagonists |
US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
WO2003082335A1 (fr) | 2002-04-03 | 2003-10-09 | Sumitomo Pharmaceuticals Co., Ltd. | Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe |
US7244555B2 (en) | 2002-05-14 | 2007-07-17 | Renovak Inc | Systems and methods for identifying organ transplant risk |
EP1554253A4 (en) | 2002-06-03 | 2006-09-20 | Smithkline Beecham Corp | IMIDAZOLIUM COMPOUNDS INHIBITORS OF CXCR3 |
WO2004113323A1 (en) * | 2003-06-13 | 2004-12-29 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
EP1856098B1 (en) * | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
EP1853583B1 (en) * | 2005-02-16 | 2011-09-07 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CA2598418A1 (en) * | 2005-02-16 | 2006-08-31 | Schering Corporation | Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
CA2598456A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Heterocyclic substituted piperazines with cxcr3 antagonist activity |
CA2598489A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
CN101146793A (zh) * | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
US7781437B2 (en) * | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
AR059962A1 (es) * | 2006-03-21 | 2008-05-14 | Schering Corp | Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3 |
CA2658417A1 (en) * | 2006-07-14 | 2008-01-17 | Schering Corporation | Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
AR064609A1 (es) | 2006-12-22 | 2009-04-15 | Schering Corp | Piperazinas sustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor de quimiocinas cxcr3. |
-
2006
- 2006-02-14 EP EP06735088A patent/EP1856097B1/en active Active
- 2006-02-14 AU AU2006214378A patent/AU2006214378A1/en not_active Abandoned
- 2006-02-14 US US11/353,697 patent/US7776862B2/en active Active
- 2006-02-14 WO PCT/US2006/005265 patent/WO2006088919A2/en active Application Filing
- 2006-02-14 JP JP2007556253A patent/JP2008530218A/ja active Pending
- 2006-02-14 KR KR1020077019138A patent/KR20070107056A/ko not_active Application Discontinuation
- 2006-02-14 CA CA002598457A patent/CA2598457A1/en not_active Abandoned
- 2006-02-14 MX MX2007009946A patent/MX2007009946A/es unknown
- 2006-02-14 CN CNA2006800126408A patent/CN101213185A/zh active Pending
- 2006-02-15 TW TW095105088A patent/TW200640901A/zh unknown
- 2006-02-15 AR ARP060100547A patent/AR055195A1/es not_active Application Discontinuation
-
2007
- 2007-08-06 IL IL185074A patent/IL185074A0/en unknown
- 2007-08-15 ZA ZA200706793A patent/ZA200706793B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006088919A3 (en) | 2006-11-02 |
EP1856097A2 (en) | 2007-11-21 |
JP2008530218A (ja) | 2008-08-07 |
MX2007009946A (es) | 2007-09-26 |
CN101213185A (zh) | 2008-07-02 |
US20070021611A1 (en) | 2007-01-25 |
IL185074A0 (en) | 2007-12-03 |
WO2006088919A2 (en) | 2006-08-24 |
EP1856097B1 (en) | 2012-07-11 |
CA2598457A1 (en) | 2006-08-24 |
US7776862B2 (en) | 2010-08-17 |
AU2006214378A1 (en) | 2006-08-24 |
TW200640901A (en) | 2006-12-01 |
ZA200706793B (en) | 2008-11-26 |
KR20070107056A (ko) | 2007-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055195A1 (es) | Piperazin-piridinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3 y composicion farmaceutica | |
AR054224A1 (es) | Piperazin- piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3 | |
AR054185A1 (es) | Piperazin- piperidinas sustituidas con piridilo y fenilo conectados por aminos con actividad antagonista de cxcr3 | |
AR053020A1 (es) | Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3 | |
AR059962A1 (es) | Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3 | |
AR064609A1 (es) | Piperazinas sustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor de quimiocinas cxcr3. | |
AR061975A1 (es) | Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3 | |
ES2873515T3 (es) | Derivado de quinolona, sal o estereoisómero del mismo farmacéuticamente aceptable, como inhibidor de AXL | |
ES2302106T3 (es) | Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina. | |
RU2011103234A (ru) | Новые фенилпиразиноны в качестве ингибиторов киназы | |
CY1112601T1 (el) | Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης | |
RU2009123930A (ru) | Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4 | |
DE60319269D1 (de) | Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen | |
MX2007001853A (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
BRPI0616701A2 (pt) | 2-amino-7,8-diidro-6h-pirido [4,3-d] pirimidin-5-onas | |
CA2664631A1 (en) | Quinoline derivatives for modulating dna methylation | |
EA200600257A1 (ru) | Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3 | |
AR039649A1 (es) | Compuestos de pirrolo-triazina anilina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen | |
AU2014373773B2 (en) | Compounds and methods of use | |
KR20180021901A (ko) | C-met 키나아제 억제제 화합물 | |
FI942112A0 (fi) | AIDS:n hoidossa käyttökelpoisia HIV-proteaasi-inhibiittoreita | |
AR037972A1 (es) | Pirrolopirimidinas | |
CA2504385A1 (en) | Thiadiazine compounds and uses thereof | |
EA200400305A1 (ru) | 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность | |
AR053357A1 (es) | Uso de un inhibidor de quinasa del receptor del factor de crecimiento epidermico (efgr) en pacientes resistentes a gefitinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |